Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Hyperthyroidism Added to Serious ADR Section of Flolan’s Package Insert
December 28, 2011
- MHLW Commission Says Joint Purchasing an Advantage to Integration of National, Rosai Hospitals
December 28, 2011
- Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
- PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
- Reevaluation Recommended for Lysozyme, Pronase
December 26, 2011
- Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
- Development Request Withdrawn for Mitoxantrone
December 26, 2011
- Application Based on Data from Public Domain Recommended for 6 APIs Including Amlodipine
December 26, 2011
- ¥25 Bil. to Be Saved through Add’l NHI Price Cuts for Both Long-listed, Generic Drugs in FY2012: MHLW
December 26, 2011
- MIPO to Begin Preparing for Drug Discovery Support Organization
December 26, 2011
- 0.9% Additional Price Cut for Long-Listed Drugs, Compensating Upward Revision of Nursing Fee: Minister Negotiation
December 22, 2011
- PAC Recommends Approval for Products Recommended by PAFSC’s Committee on Drugs
December 22, 2011
- CSIMC Approves Additional Price Reduction for Long-listed Drugs Next Year
December 22, 2011
- Sanofi-aventis Selected for METI Subsidy to Build Regional HQ in Japan
December 22, 2011
- Price Cut Negotiations for Long-Listed Products Between MOF, Health Ministers “Parallel”
December 21, 2011
- Pharmaceutical Affairs Strategy Consultation: 98 Registrations for Preliminary Meetings, Increasing Numbers from Universities
December 21, 2011
- PMDA to Provide Prior Assessment Consultation Service for 10 APIs in FY2011
December 21, 2011
- Gov’t Approves 4th Supplementary Budget at Cabinet Meeting, Prolongs Public Subsidy for Vaccine Programs
December 21, 2011
- Bill Payers Seek Revision of Ryotan-kisoku to Increase Generic-name Prescriptions
December 21, 2011
- Chuikyo Approves Plan to Revise DPC System
December 21, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…